The FDA approved the use of encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma) in combination for patients
Publications
FDA approves combo treatment for melanoma
The combination of encorafenib and binimetinib (Braftovi and Mektovi) has been granted approval by the U.S. Food and Drug Administration
NIH Genetics Home Reference – Melanoma
Melanoma is a type of skin cancer that begins in pigment-producing cells called melanocytes.
FDA Approves Drug Duo for BRAF-Positive Melanoma
The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.